Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD (NCT06324448) | Clinical Trial Compass
CompletedNot Applicable
Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD
South Korea24 participantsStarted 2024-02-15
Plain-language summary
The purpose of this study is to investigate the efficacy and safety of self-administered transcranial direct current stimulation to improve the single- and dual-task gait in patients with Parkinson's disease.
Who can participate
Age range19 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinically diagnosed as idiopathic Parkinson's disease by neurologists according to the UK Parkinson's Disease Society Brain Bank criteria
* modified Hoehn \& Yahr stage 2, 2.5, or 3
Exclusion Criteria:
* History of seizure
* Metallic implants, such as cardiac pacemaker or an artificial cochlea
* Patients with inflammation, burns, or wounds in the stimulation area
* Parkinson's disease dementia; cut-off is \< 7 of Korean-Montreal Cognitive Assessment for illiterate patients, \< 13 for those educated for 0.5-3 years, \< 16 for 4-6 years of education, \< 19 for 7-9 years of education, and \< 20 for 10 or more years of education.
* Severe dyskinesia or severe on-off phenomenon
* Plan to adjust medication at the time of screening
* Other neurological, orthopedic, or cardiovascular co-morbidities significantly affecting gait function
* Uncontrolled vestibular disease, orthopedic hypotension, or paroxysmal vertigo
* Pregnant or lactating patients
* Other comorbidities that make it difficult to participate in this study
What they're measuring
1
Timed-up and go test (sec)
Timeframe: Immediate post-intervention
2
Timed-up and go test under dual-task condition (sec)